Biomerieux, Inc.

Geneuro Sa

Centre National De La Recherche Scientifique

Institut National De La Sante Et De La Recherche Medicale

Universite Claude Bernard – Lyon1

Université Joseph Fourier

Biomerieux Sa

Université Joseph Fourier - Grenoble 1

Agence Francaise De Securite Sanitaire Des Aliments

Agence Francaise De Securite Sanitaire Des Aliments-afssa

Universite Claude Bernard Lyon and Biomerieux

Colette Jolivet-reynaud

Herve Perron

Florence Komurian-pradel

Glaucia Paranhos-baccala

Bernard F Mandrand

Frederic Bedin

Frederic Beseme

Francois Mallet

Glaucia Paranhos-Baccala

Florence Komurian-Pradel

Colette Jolivet-Reynaud

Jean-Marie Seigneurin

Alois Bernhardt Lang

Jean-Baptiste Bertrand

Corinne Bernard

Anthony William Coleman

Eric Da Silva

Raphaël Faucard

Aly Moussa

Marilyne Dupin

Alexandra Madeira

Ambroise Martin

Edwige Leclere

Mireille Sodoyer

Catherine Ott

Francedillaois Rieger

Tomas Dobransky

Raphael Faucard

Marie-Helene Charles

Patrick Küry

Hanno V Kolbe

Julie Medina

Patrice Marche

Lyse Santoro

Frederic Ronzon

Dominique Roecklin

Carine Malcus

Julie Joanou

Patrick Shahgaldian

Jeremy Alexander Garson

Philip William Tuke

Reza Firouzi

Adina Nicoleta Lazar

Carine Malcus-Vocanson

Nadege Gehin

Francois Curtin

Alexandre Rolland

Evelyne Jouvin-Marche

Anna Benscik-Reynier

Patrick Kury

Bernard Mandrand

Alois Lang

The invention relates to an antibody, a fragment or a derivative thereof, for use as an antiretroviral drug targeting a virus belonging to human endogenous retroviruses type W (HERV-W), wherein said antibody, fragment or derivative thereof is directed against HERV-W Envelope protein (HERV-W Env). The invention also relates to a composition comprising said antibody and a retroviral reverse-transcriptase inhibitory drug, for use as an antiretroviral drug targeting a virus belonging to HERV-W.

Antiretroviral drug targeting human endogenous retrovirus

The present invention deals with innovative compounds and compositions for preventing and/or treating a newly discovered detrimental mechanism, which blocks the endogenous myelin repair capacity of the adult nervous system (NS) in diseases associated with the expression of HERV-W envelope protein (ENV), in particular of its MSRV subtype.

Compounds for treating the remyelination blockade in diseases associated with the expression of HERV-W envelope protein

A ligand includes each of the complementary-determining regions (CDRs) set forth in SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 3 SEQ ID No. 4, SEQ ID No. 5 and SEQ ID No. 6 or any sequence having either number of substituted aminoacids within said sequences as indicated in the following, from 0 to 3 in CDR1 (SEQ ID No.1), from 0 to 2 in CDR2 (SEQ ID No.2), from 0 to 2 in CDR3 (SEQ ID No.3), from 0 to 1 in CDR4 (SEQ ID No.4), from 0 to 4 in CDR5 (SEQ ID No.5), from 0 to 2 in CDR6 (SEQ ID No.6), or aminoacids substituted with other aminoacids having equivalent chemical functions and properties, within said sequences SEQ ID No. 1 to SEQ ID No. 6.

Therapeutic use of specific ligand in MSRV associated diseases

The present invention deals with a ligand comprising each of the complementary-determining regions (CDRs) set forth in SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 3 SEQ ID No. 4, SEQ ID No. 5 and SEQ ID No. 6 or sequence having either number of substituted aminoacids within said sequences as indicated in the following, from 0 to 3 in CDR1(SEQ ID No. 1), from 0 to 2 in CDR2(SEQ ID No. 2), from 0 to 2 in CDR3(SEQ ID No. 3), from 0 to 1 in CDR4(SEQ ID No. 4), from 0 to 4 in CDR5(SEQ ID No. 5), from 0 to 2 in CDR6(SEQ ID No. 6), or aminoacids substituted with other aminoacids having equivalent chemical functions and properties, within said sequences SEQ ID No. 1 to SEQ ID No. 6.

An isolated polynucleotide having a nucleotide sequence selected from the group consisting of (a) SEQ ID NO: 21, (b) the full-length sequences encoding a polypeptide having a peptide sequence selected from the group consisting of SEQ ID NOs: 25 and 26, and (c) the full-length complementary sequences to the sequences set forth in (a) or (b).

Isolated multiple sclerosis (MS)-associated retrovirus (MSRV) nucleic acids corresponding to the gag region

Viral material, in the isolated or purified state, in which the genome comprises a nucleotide sequence chosen from the group including sequences SEQ ID NO:46, SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:53 and SEQ ID NO:56, their complementary sequences and their equivalent sequences, in particular nucleotide sequences displaying, for any succession of 100 contiguous monomers, at least 50% and preferably at least 70% homology with the said sequences SEQ ID NO:46, SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:53 and SEQ ID NO:56, respectively, and their complementary sequences.

Viral material and nucleotide fragments associated with multiple sclerosis, for diagnostic, prophylactic and therapeutic purposes

The invention concerns a nucleic material, in isolated or purified state, and a nucleotide fragment comprising a nucleotide sequence selected from the group consisting in (i) the sequences SEQ ID NO: 112, SEQ ID NO:114, SEQ ID NO: 117, SEQ ID NO: 120, SEQ ID NO. 124, SEQ ID NO: 130, SEQ ID NO: 141 and SEQ ID NO: 142, (ii) the complementary sequences of sequences (i); and (iii) the sequences equivalent to sequences (ii) and (iii), in particular the sequence having for every series of 100 contiguous monomers, at least 50%, preferably 70% homology with sequences (i) and (ii) respectively. The invention also concerns their uses for detecting a retrovirus associated with multiple sclerosis and/or rheumatoid arthritis.

Multiple sclerosis-associated retroviral (MSRV) nucleic acids corresponding to the Env region

The invention provides viral material and nucleotide fragments associated with multiple sclerosis and/or rheumatoid arthritis for use in method of diagnosis, prophylaxis, and therapy.

The inventive composition comprises at least one type of antibody selected in a group (i) of anti-Env-SU MSRV/HERV-W antibodies or in a group of anti-TLR4 antibodies specifically linkable with the soluble fraction of an Env protein of MSRV/HERV-W or to a TLR4 receptor of the soluble fraction of the Env protein of MSRV/HERV-W.

Composition for treating pathology associated with MSRV/HERV-W

The invention relates to a method for detecting PrP in a biological human or animal sample that may contain PrP. The inventive method is characterised in that it uses a molecule containing at least one positive charge and/or at least one osidic bond and a ligand other than a proteinic ligand selected from macrocyclic ligands and glycosaminoglycanes.

Method for detecting PrP using at least one positive charge and/or at least one glycosidic bond and a ligand other than a protein ligand

The invention concerns the use of at least one polypeptide comprising a protein fragment to obtain a diagnostic, prognostic, prophylactic or therapeutic composition for detecting, preventing or treating a pathological condition associated with a degenerative and/or neurological and/or autoimmune disease, said protein being selected among the proteins whereof the peptide sequence in native state corresponds to SEQ ID No 1, SEQ ID No 2, SEQ ID No 3, SEQ ID No 4, SEQ ID No 5, SEQ ID No 6, SEQ ID No 7, SEQ ID No 8, SEQ ID No 9, SEQ ID No 10, SEQ ID No 11, SEQ ID No 12, SEQ ID No 13, SEQ ID No 14, SEQ ID No 15, SEQ ID No 16, SEQ ID No 17, SEQ ID No 18, SEQ ID No 19, SEQ ID No 20, SEQ ID No 21, SEQ ID No 22, SEQ ID No 23, SEQ ID No 24, SEQ ID No 25, SEQ ID No 26, SEQ ID No 27, SEQ ID No 28, and SEQ ID No 29, and the peptide sequences having at least 70% identity, preferably at least 80% identity and advantageously at least 98% identity with any one of the peptide sequences SEQ ID No 1 to SEQ ID No 8 and SEQ ID No 10 to SEQ ID No 29, and the peptide sequences or fragments of said sequences belonging to a common family of proteins selected among perlecan, the precursor of the retinol-binding plasmatic protein, of the GM2 activator protein, of calgranulin B and of saponin B.

Use of a polypeptide for detecting, preventing or treating a pathological condition associated with a degenerative, neurological or autoimmune disease

The invention relates to: a nucleotide fragment of an MSRV-1 LTR-RU5 region, comprising a nucleotide sequence encoding the expression of a protein, wherein the protein comprises a peptide sequence selected from the group consisting of: SEQ ID NO: 2, SEQ ID NO: 3, and SEQ ID NO: 4; complementary nucleotide fragments; probes and primers that hybridize to the fragment; proteins encoded by the fragment; antibodies directed against the proteins encoded by the fragment; and processes for detecting the presence of MSRV-1 using a probe or an antibody of the invention.

LTR region of MSRV-1 and the proteins it encodes, and probes and methods for detecting MSRV-1 retrovirus

A process for detecting the forms of the prion pathogens responsible for subacute, transmissible, spongiform encephalopathies, including a macrocyclic adjuvant ligand (AML), free or bound to a support, that is added to a biological sample capable of containing PrP, the resulting suspension then being reacted with an anti-PrPantibody, and the presence of PrP is then detected.

Process for detecting PrP using a macrocyclic adjuvant ligand

Growing community of inventors

Saint Genis les Ollieres, France

Herve Perron